These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 10853886)

  • 21. Guidelines for European workplace drug testing in oral fluid.
    Cooper G; Moore C; George C; Pichini S;
    Drug Test Anal; 2011 May; 3(5):269-76. PubMed ID: 21538943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HAIRVEQ: an external quality control scheme for drugs of abuse analysis in hair.
    Pichini S; Ventura M; Pujadas M; Ventura R; Pellegrini M; Zuccaro P; Pacifici R; de la Torre R
    Forensic Sci Int; 2004 Oct; 145(2-3):109-15. PubMed ID: 15451081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ORALVEQ: external quality assessment scheme of drugs of abuse in oral fluid: results obtained in the first round performed in 2007.
    Ventura M; Ventura R; Pichini S; Leal S; Zuccaro P; Pacifici R; Langohr K; de la Torre R
    Forensic Sci Int; 2008 Nov; 182(1-3):35-40. PubMed ID: 19004584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Should NPS be included in workplace drug testing?
    Salomone A; Palamar JJ; Vincenti M
    Drug Test Anal; 2020 Feb; 12(2):191-194. PubMed ID: 31840414
    [No Abstract]   [Full Text] [Related]  

  • 25. [Analysis of tools, methods and results of toxicological screening for detection of drug abuse in Italian professional drivers].
    Rosso GL
    Med Lav; 2013; 104(1):30-43. PubMed ID: 23520885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New technology and new initiatives in U.S. workplace testing.
    Walsh JM
    Forensic Sci Int; 2008 Jan; 174(2-3):120-4. PubMed ID: 17434275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Drug abuse tests important part of preventive measures against narcotics. With testing drug abuse can be identified early in the workplace].
    Hermansson U; Beck O; Westregård A; Brunes M
    Lakartidningen; 2010 Nov 17-23; 107(46):2878-80. PubMed ID: 21197782
    [No Abstract]   [Full Text] [Related]  

  • 28. HAIRVEQ 2006: evolution of laboratories' performance after different educational actions.
    Ventura M; Stramesi C; Pichini S; Ventura R; Pujadas M; Di Giovannandrea R; Zuccaro P; Pacifici R; Langohr K; de la Torre R
    Forensic Sci Int; 2008 Mar; 176(1):2-8. PubMed ID: 17980986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Finnish guidelines for workplace drug testing.
    Lillsunde P; Haavanlammi K; Partinen R; Mukala K; Lamberg M
    Forensic Sci Int; 2008 Jan; 174(2-3):99-102. PubMed ID: 17499950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral fluid for workplace drug testing: laboratory implementation.
    Moore C
    Drug Test Anal; 2012 Feb; 4(2):89-93. PubMed ID: 21916024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Special report. Drug testing in the workplace: an update.
    Hosp Secur Saf Manage; 1994 Oct; 15(6):5-9. PubMed ID: 10137771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Should informed consent be required for laboratory testing for drugs of abuse in medical settings?
    Warner EA; Walker RM; Friedmann PD
    Am J Med; 2003 Jul; 115(1):54-8. PubMed ID: 12867235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemical dependency and drug testing in the workplace.
    Osterloh JD; Becker CE
    West J Med; 1990 May; 152(5):506-13. PubMed ID: 2190418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug-free workplace programmes: New Zealand perspective.
    Nolan S
    Forensic Sci Int; 2008 Jan; 174(2-3):125-32. PubMed ID: 17467938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Workplace testing of drugs of abuse and psychotropic drugs].
    Mura P; Saussereau E; Brunet B; Goullé JP
    Ann Pharm Fr; 2012 May; 70(3):120-32. PubMed ID: 22655580
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Consensus document on European brain research.
    Olesen J; Baker MG; Freund T; di Luca M; Mendlewicz J; Ragan I; Westphal M
    J Neurol Neurosurg Psychiatry; 2006 Aug; 77 Suppl 1(Suppl 1):i1-49. PubMed ID: 16845120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interpretation of Workplace Tests for Cannabinoids.
    Kulig K
    J Med Toxicol; 2017 Mar; 13(1):106-110. PubMed ID: 27686239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Marijuana in the Workplace: Guidance for Occupational Health Professionals and Employers: Joint Guidance Statement of the American Association of Occupational Health Nurses and the American College of Occupational and Environmental Medicine.
    Phillips JA; Holland MG; Baldwin DD; Gifford-Meuleveld L; Mueller KL; Perkison B; Upfal M; Dreger M
    Workplace Health Saf; 2015 Apr; 63(4):139-64. PubMed ID: 25862727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Illicit drugs, testing, prevention and work in France: ethical and legal issues.
    Fantoni-Quinton S; Bossu B; Morgenroth T; Frimat P
    Med Law; 2010 Sep; 29(3):353-72. PubMed ID: 22145557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Finnish legislation on workplace drug testing.
    Lamberg ME; Kangasperko R; Partinen R; Lillsunde P; Mukala K; Haavanlammi K
    Forensic Sci Int; 2008 Jan; 174(2-3):95-8. PubMed ID: 17498899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.